Tear Protein Lacritin in Human Tears
Conditions
Keywords
Lacritin
Brief summary
Purpose: to build a library of normal tear lacritin values by collecting tears from normal adult human subjects and to develop a non-invasive clinical assay for lacritin. Such an assay will provide more sensitive indicators of eye disease for clinicians and determine if a particular therapy, such as recombinant lacritin drops, is of benefit.
Interventions
PROCEDURETear Collection
The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
Sponsors
University of Virginia
James Madison University
Eastern Virginia Medical School
Walter Reed Army Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Military health care beneficiary between the ages of 21-55. 2. Male or female, of any race, and at least 21 years old and not older than 55 years old at the time of tear collection. 3. Appropriately aged individuals who report that their eyes are normal and who have no active eye illness as determined by principal investigator or sub-investigator. 4. Ability and willingness to understand and provide informed consent to participate in this study.
Exclusion criteria
1. Irritated eye reflected by patient statements or finding of red eye. 2. Individuals with any infections or inflammatory ocular condition (e.g. have pink eye or uveitis). 3. Individuals diagnosed with dry eye or other ocular surface condition, including but not restricted to neurotrophic keratitis, anterior basement membrane dystrophy, and recurrent corneal erosions. 4. Individuals who are on any topical eye medications. 5. Anyone who reports previous reaction or the possibility of an allergic reaction to 0.5% proparacaine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lacritin levels in human tears | 2 minutes after instilling anesthetic eyedrop |
Countries
United States
Outcome results
None listed